The LAMA* aclidinium bromide was similarly effective in reducing exacerbation rate without raising the risk of MACE** or all-cause mortality regardless of recent history of exacerbations in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD), according to a subgroup analysis of the phase IV ASCENT-COPD*** trial presented at the CHEST 2019 Annual Meeting.
The lung damage acquired from smoking persists years after smoking cessation, with a faster decline in lung function in former smokers compared with never-smokers, according to a recent US-based study.
Consistent with clinical trial data, the use of biologic therapies significantly reduced asthma exacerbations in addition to having steroid-sparing effects in patients with severe, refractory asthma who were dependent on oral steroids, according to a real-world study presented at the annual CHEST Meeting 2019 held in New Orleans, Louisiana, US.
While adding varenicline to weekly counselling for smoking cessation did not improve abstinence rates among adolescent smokers at the end of treatment, it may promote earlier abstinence and sustained response to varenicline post-treatment, a study finds.
Treatment without antibiotic medication does not appear to be inferior to moxifloxacin therapy as regards treatment failure or length of stay (LOS) among patients with chronic obstructive pulmonary disease (COPD) requiring hospitalization for nonpurulent exacerbation, according to the results of a study presented at the European Respiratory Society (ERS) International Congress 2019.
Antibiotic prophylaxis with azithromycin in individuals with primary antibody deficiencies (PAD) may lead to a reduced risk of respiratory exacerbations, according to a phase II trial presented at ERS 2019.
About one-third of patients with severe asthma who are on high-dose inhaled corticosteroids (ICS) are also receiving excessive doses of oral corticosteroids (OCS), reveals a study presented at the ERS 2019 Meeting.
The immediate reduction of cigarette nicotine content results in greater improvements in levels of smoke exposure biomarkers than gradual reduction, though withdrawal symptoms are stronger, according to a recent study.